Pacesa argues that closed-source models won't significantly outperform open-source tools because most rely on the same public PDB data. The true competitive advantage lies not in tweaking algorithms but in generating massive, proprietary, high-quality experimental datasets that can train genuinely superior models.

Public internet data has been largely exhausted for training AI models. The real competitive advantage and source for next-generation, specialized AI will be the vast, untapped reservoirs of proprietary data locked inside corporations, like R&D data from pharmaceutical or semiconductor companies.

In the AI era, models and compute infrastructure have near-zero switching costs and are becoming commoditized. A company's unique, historical data is emerging as its most valuable and defensible asset. This proprietary data, once archived and ignored, is now the key differentiator and competitive moat.

The company's core strategy is generating unique, high-resolution epigenetic data that doesn't exist publicly. This data becomes the defensible asset, as AI models built on common public datasets are less effective and lack a true competitive edge.

Since LLMs are commodities, sustainable competitive advantage in AI comes from leveraging proprietary data and unique business processes that competitors cannot replicate. Companies must focus on building AI that understands their specific "secret sauce."

As powerful foundation models like GPT become commodities, a company's defensible moat is no longer its algorithm but its proprietary, hard-to-replicate dataset. The value lies in the unique data you can feed into these common models, as it's the one thing that is not easily found or replaced online.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

The competitive advantage in pharma isn't the sophistication of an AI algorithm, which is often a commodity built on third-party models. The true differentiator is the quality, relevance, and end-to-end consistency of the proprietary data used to train and validate these models. Poor data invalidates even the best analytics.

As algorithms become more widespread, the key differentiator for leading AI labs is their exclusive access to vast, private data sets. XAI has Twitter, Google has YouTube, and OpenAI has user conversations, creating unique training advantages that are nearly impossible for others to replicate.